Global Trust Asset Management LLC Sells 300 Shares of Eli Lilly and Company (NYSE:LLY)

Global Trust Asset Management LLC trimmed its position in Eli Lilly and Company (NYSE:LLY) by 23.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,002 shares of the company’s stock after selling 300 shares during the quarter. Global Trust Asset Management LLC’s holdings in Eli Lilly and Company were worth $780,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. Simon Quick Advisors LLC boosted its stake in shares of Eli Lilly and Company by 10.5% in the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after buying an additional 278 shares during the period. Independent Advisor Alliance lifted its position in shares of Eli Lilly and Company by 1.7% during the 4th quarter. Independent Advisor Alliance now owns 32,269 shares of the company’s stock valued at $18,810,000 after acquiring an additional 544 shares during the period. Apexium Financial LP grew its holdings in shares of Eli Lilly and Company by 1,819.1% during the 4th quarter. Apexium Financial LP now owns 11,438 shares of the company’s stock worth $6,667,000 after purchasing an additional 10,842 shares in the last quarter. Clear Harbor Asset Management LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter worth $363,000. Finally, Terril Brothers Inc. raised its stake in Eli Lilly and Company by 113.2% in the fourth quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after purchasing an additional 429 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Up 0.8 %

Shares of LLY stock opened at $890.62 on Tuesday. Eli Lilly and Company has a 1-year low of $434.34 and a 1-year high of $905.45. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The stock has a market cap of $846.45 billion, a price-to-earnings ratio of 131.17, a PEG ratio of 1.93 and a beta of 0.36. The stock has a 50-day moving average of $801.37 and a 200-day moving average of $732.02.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter in the prior year, the firm posted $1.62 EPS. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. On average, equities research analysts forecast that Eli Lilly and Company will post 13.73 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 10th. Investors of record on Thursday, May 16th were issued a $1.30 dividend. The ex-dividend date of this dividend was Wednesday, May 15th. This represents a $5.20 annualized dividend and a yield of 0.58%. Eli Lilly and Company’s payout ratio is 76.58%.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, major shareholder Lilly Endowment Inc sold 9,671 shares of the stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $902.67, for a total transaction of $8,729,721.57. Following the transaction, the insider now directly owns 97,574,139 shares of the company’s stock, valued at $88,077,248,051.13. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 772,475 shares of company stock valued at $656,838,859. 0.13% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

LLY has been the subject of several analyst reports. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Bank of America restated a “buy” rating and set a $1,000.00 price objective on shares of Eli Lilly and Company in a research report on Monday. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a report on Monday. Finally, JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $806.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.